Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world
M Million, P Gautret, P Colson, Y Roussel, G Dubourg, E Chabriere, S Honore, J-M Rolain, F Fenollar, P-E Fournier, J-C Lagier, P Parola, P Brouqui, D Raoult
New Microbes and New Infections, doi:10.1016/j.nmni.2020.100709
In the context of the current coronavirus disease 2019 (COVID-19) pandemic, we conducted a meta-analysis on the effects of chloroquine derivatives in patients, based on unpublished and published reports available publicly on the internet as of 27 May 2020. The keywords 'hydroxychloroquine', 'chloroquine', 'coronavirus', 'COVID-19' and 'SARS-Cov-2' were used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language. Twenty studies were identified involving 105 040 patients (19 270 treated patients) from nine countries (
Declaration of competing interest The authors declare no competing interests. Funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. Our group used widely available generic drugs distributed by many pharmaceutical companies.
Appendix A. Supplementary data Supplementary data to this article can be found online at https:// doi.org/10.1016/j.nmni.2020.100709.
References
Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog,
doi:10.1016/j.micpath.2020.104228Ashraf, Shokouhi, Shirali, Davari-Tanha, Memar et al., COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes,
doi:10.1101/2020.04.20.20072421Barbosa Esper, Da Silva, Costa Oikawa, Castro, Razuk-Filho et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Baudrillard, Simulacres et Simulation
Borba, Val, Sampaio, Alexandre, Melo et al., CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.8857Carlucci, Ahuja, Petrilli, Rajagopalan, Jones et al., Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv,
doi:10.1101/2020.05.02.20080036Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv,
doi:10.1101/2020.03.22.20040758Davido, Lansaman, Bessis, Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?,
doi:10.1101/2020.05.05.20088757v1De Novales, Ramírez-Olivencia, Estébanez, De Dios, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: An observational study, Preprints,
doi:10.20944/preprints202005.0057.v1Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Guerin, Lardenois, Levy, De Andreis, Sarrazin et al., + hydroxychloroquine). Rapport d'expérience de médecins de terrain Recommandations diagnostiques et thérapeutiques à l'usage de leurs consoeurs et confrères
Huang, Li, Xiao, Liang, Pang et al., Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, medRxiv,
doi:10.1101/2020.04.26.20081059Lagier, Aubry, Delord, Michelet, Tissot-Dupont et al., From expert protocols to standardized management of infectious diseases, Clin Infect Dis
Lagier, Fenollar, Lepidi, Roch, Million et al., Treatment of classic Whipple's disease: from in vitro results to clinical outcome, J Antimicrob Chemother
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101791Lagier, Million, Raoult, Bouillabaisse or fish soup: the limitations of meta-analysis confronted to the inconsistency of fecal microbiota transplantation studies, Clin Infect Dis,
doi:10.1093/cid/ciz707Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv,
doi:10.1101/2020.04.16.20065920Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv,
doi:10.1101/2020.04.10.20060699Mehra, Desai, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet. Published online,
doi:10.1016/S0140-6736(20)31180-6Melenotte, Protopopescu, Million, Edouard, Carrieri et al., Clinical features and complications of Coxiella burnetii infections from the French National Reference Center for Q fever, JAMA Netw Open
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101738Million, Raoult, Relevance of medical big data analysis depends on clinical accuracy: the Q fever paradigm, Clin Infect Dis
Muchielli, Le, De, Mucchielli, None
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-Hospital mortality in patients with COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Shabrawishi, Naser, Aldobyany, Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions,
doi:10.1101/2020.05.08.20095679v1Shabrawishi, Naser, Alwafi, Aldobyany, Touman, Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions, medRxiv,
doi:10.1101/2020.05.08.20095679Singh, Khan, Chowdhry, Chatterjee, Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-real-world evidence from a federated electronic medical record network, medRxiv,
doi:10.1101/2020.05.12.20099028Tan, Wang, Zhang, Ding, Huang et al., Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduct Target Ther,
doi:10.1038/s41392-020-0148-4Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial,
doi:10.1101/2020.04.10.20060558Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial,
doi:10.1101/2020.04.10.20060558Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Yanturali, Aksay, Demir, Atilla, Massive hydroxychloroquine overdose, Acta Anaesthesiol Scand
Yu, Li, Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19, medRxiv,
doi:10.1101/2020.04.27.20073379
